EUVIMEDEUVIMED entdecken
VergleichsstudieNetzwerk-MetaanalyseSystematische Übersicht

Comparison of the efficacy and safety of GLP ‐1 receptor agonists on cardiovascular events and risk factors: A review and network meta‐analysis

Xuedong An iD, WenJie Sun iD, Zhige Wen, LiYun Duan, YueHong Zhang, Xiaomin Kang, Hangyu Ji, Yuting Sun, Linlin Jiang, Xuefei Zhao, Qing Gao, Fengmei Lian iD

Diabetes, Obesity and Metabolism · 2025

DOI: 10.1111/dom.16228 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Xuedong An und 11 weiteren Autor:innen. Beteiligte Einrichtung: Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Beijing, China. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Young Elite Scientists Sponsorship Program by CACM, High Level Chinese Medical Hospital Promotion Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aims to systematically evaluate and perform a systematic review and network meta‐analysis comparing the comprehensive cardiovascular protective effects of various glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), focusing on cardiovascular events and risk factors.

Methods

We searched PubMed, Embase, Cochrane Library and Web of Science from inception to December 15, 2024. Included studies were published randomized controlled trials (RCTs) comparing GLP‐1RAs to placebo or other GLP‐1RAs. Missing data were standardized, and network meta‐analysis was performed using Stata 17.0. Study heterogeneity, publication bias and evidence quality were assessed using the Cochrane Risk of Bias tool and Confidence in Network Meta‐Analysis (CINeMA).

Results

As of December 15, 2024, a total of 18 313 articles were retrieved. Based on the inclusion and exclusion criteria, 156 high‐quality studies were included, incorporating 144 782 patients and 14 different GLP‐1RAs. The network meta‐analysis demonstrated low heterogeneity, ensuring the reliability of the results. Comprehensive analysis revealed the following: Efpeglenatide was the most effective in reducing major adverse cardiovascular events. Oral semaglutide shows more significant advantages in reducing all‐cause mortality and cardiovascular mortality. Orforglipron excelled in glycaemic control and weight reduction. SC‐Semaglutide showed the greatest efficacy in lowering both systolic blood pressure and diastolic blood pressure, Liraglutide showed the greatest efficacy in lowering total cholesterol, Noiiglutide in triglycerides and Taspoglutide in low‐density lipoprotein cholesterol, but no GLP‐1RAs in high‐density lipoprotein cholesterol. GLP‐1RAs did not significantly increase the incidence of adverse events, but Orforglipron and Taspoglutide significantly increased the incidence of gastrointestinal adverse events compared with placebo.

Conclusion

This study compared the cardiovascular benefits of different GLP‐1RAs, including reductions in cardiovascular events and improvements in multiple cardiovascular risk factors. However, due to limitations in the quantity and quality of the included studies, the conclusions should be interpreted with caution. Future large‐scale, high‐quality clinical trials are needed to validate these findings and further optimize comprehensive cardiovascular management strategies for patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesDiabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsHumansHeart Disease Risk FactorsRandomized Controlled Trials as TopicRisk FactorsTreatment Outcome

Stichwörter der Autor:innen

GLP‐1 receptor agonistscardiovascular eventscardiovascular risk factorsnetwork meta‐analysissystematic review

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic Agents

Autor:innen und Institutionen

  • Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Beijing, China.
  • Shandong University of Traditional Chinese Medicine, Jinan, China.
  • Fangshan Hospital Beijing University of Chinese Medicine, Beijing, China.

ORCID-Profile: Xuedong An, WenJie Sun, Fengmei Lian

Förderung

  • National Natural Science Foundation of China
  • Young Elite Scientists Sponsorship Program by CACM
  • High Level Chinese Medical Hospital Promotion Project
  • Escort Project of Guang'anmen Hospital, Chinese Academy of Traditional Chinese Medicine

Zitieren

APA

An, X., Sun, W., Wen, Z., Duan, L., Zhang, Y., Kang, X., Ji, H., Sun, Y., Jiang, L., Zhao, X., Gao, Q., & Lian, F. (2025). Comparison of the efficacy and safety of GLP ‐1 receptor agonists on cardiovascular events and risk factors: A review and network meta‐analysis. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16228

Vancouver

An X, Sun W, Wen Z, Duan L, Zhang Y, Kang X, et al. Comparison of the efficacy and safety of GLP ‐1 receptor agonists on cardiovascular events and risk factors: A review and network meta‐analysis. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16228

BibTeX
@article{An2025,
  author = {An, Xuedong and Sun, WenJie and Wen, Zhige and Duan, LiYun and Zhang, YueHong and Kang, Xiaomin and Ji, Hangyu and Sun, Yuting and Jiang, Linlin and Zhao, Xuefei and Gao, Qing and Lian, Fengmei},
  title = {Comparison of the efficacy and safety of GLP ‐1 receptor agonists on cardiovascular events and risk factors: A review and network meta‐analysis},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  doi = {10.1111/dom.16228}
}
Kostenlos starten →